COVID-19 vaccine immunogenicity in people with HIV

Simple item page

Simple item page

Full item details

creativework.keywords - en
AIDS Vaccines*
Antibodies
COVID-19 Vaccines
COVID-19* / prevention & control
Canada
HIV Infections*
Humans
Immunogenicity, Vaccine
Prospective Studies
RNA, Viral
SARS-CoV-2
dc.contributor.author
Costiniuk, Cecilia T.
Galipeau, Yannick
Harris, Marianne
Hull, Mark
Brumme, Zabrina L.
Lapointe, Hope R.
Brockman, Mark A.
Margolese, Shari
Mandarino, Enrico
Samarani, Suzanne
Vulesevic, Branka
Lebouché, Bertrand
Angel, Jonathan B.
Routy, Jean-Pierre
Cooper, Curtis L.
Anis, Aslam H.
Lee, Terry
Kovacs, Colin
Jenabian, Mohammad-Ali
Chambers, Catharine
Brockman, Mark A.
Samji, Hasina
Burchell, Ann N.
Ostrowski, Mario
Tan, Darrell H. S.
Walmsley, Sharon
Singer, Joel
Hull, Mark
Brumme, Zabrina L.
Lapointe, Hope R.
dc.date.accessioned
2024-07-15T20:18:31Z
dc.date.available
2024-07-15T20:18:31Z
dc.date.issued
2023-01-01
dc.description.abstract - en
OBJECTIVES: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Our objective was to compare COVID-19 vaccine immunogenicity in PWH to HIV-negative individuals. DESIGN: In a Canadian multi-center prospective, observational cohort of PWH receiving at least two COVID-19 vaccinations, we measured vaccine-induced immunity at 3 and 6 months post 2nd and 1-month post 3rd doses. METHODS: The primary outcome was the percentage of PWH mounting vaccine-induced immunity [co-positivity for anti-IgG against SARS-CoV2 Spike(S) and receptor-binding domain proteins] 6 months post 2nd dose. Univariable and multivariable logistic regressions were used to compare COVID-19-specific immune responses between groups and within subgroups. RESULTS: Data from 294 PWH and 267 controls were analyzed. Immunogenicity was achieved in over 90% at each time point in both groups. The proportions of participants achieving comparable anti-receptor-binding domain levels were similar between the group at each time point. Anti-S IgG levels were similar by group at month 3 post 2nd dose and 1-month post 3rd dose. A lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose [92% vs. 99%; odds ratio: 0.14 (95% confidence interval: 0.03, 0.80; P = 0.027)]. In multivariable analyses, neither age, immune non-response, multimorbidity, sex, vaccine type, or timing between doses were associated with reduced IgG response. CONCLUSION: Vaccine-induced IgG was elicited in the vast majority of PWH and was overall similar between groups. A slightly lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose demonstrating the importance of timely boosting in this population.
dc.description.sponsorship
Supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (grant number: 2122-HQ-000075), and the CTN (grant number: N/A). Production of COVID-19 reagents was financially supported by the National Research Council of Canada (NRC)'s Pandemic Response Challenge Program.
dc.identifier.doi
https://doi.org/10.1097/QAD.0000000000003429
dc.identifier.issn
1473-5571
dc.identifier.pubmedID
36476452
dc.identifier.uri
https://open-science.canada.ca/handle/123456789/2692
dc.language.iso
en
dc.publisher
Wolters Kluwer Health, Inc.
dc.rights - en
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr
Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.openaccesslevel - en
Gold
dc.rights.openaccesslevel - fr
Or
dc.rights.uri - en
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en
Health
dc.subject - fr
Santé
dc.subject.en - en
Health
dc.subject.fr - fr
Santé
dc.title - en
COVID-19 vaccine immunogenicity in people with HIV
dc.type - en
Article
dc.type - fr
Article
local.article.journalissue
1
local.article.journaltitle
AIDS
local.article.journalvolume
37
local.pagination
F1-F10
local.peerreview - en
Yes
local.peerreview - fr
Oui
Download(s)

Original bundle

Now showing 1 - 1 of 1

Thumbnail image

Name: costiniuk-covid-19-vaccine-immunogenicity-in-people-with-hiv.pdf

Size: 704.5 KB

Format: PDF

Download file

Page details

Date modified: